Colorectal Cancer

Novel Immunotherapeutic Vaccine Studied in Colorectal Cancer

Patients with advanced colorectal cancer mounted a robust response to an experimental vaccine and low-dose cyclophosphamide, and strong responses were associated with improvements in survival in a phase I/II clinical trial of modified vaccinia virus Ankara–5T4 (TroVax).1


Gastroesophageal Cancer

Early PET Imaging May Guide Treatment Decisions in Esophageal Cancer

In patients with resectable esophageal or gastroesophageal junction cancer, positron-emission tomography (PET) imaging was used to assess response to induction chemotherapy. PET nonresponders were identified after the first few cycles and were switched to an alternate regimen. This strategy greatly improved the patients’ chances of achieving a pathologic complete response, researchers reported at the 2017 Gastrointestinal Cancers Symposium.


Hepatobiliary Cancer

Nivolumab Shows Benefit in Advanced Hepatocellular Carcinoma

In patients with advanced hepatocellular carcinoma, treatment with nivolumab (Opdivo) resulted in responses and long-term survival in patients who were either previously treated or naive to sorafenib (Nexavar), CheckMate 040 has shown.1



More Top Stories

Issues in Oncology

Julie Bryar Porter, MS, on Improving Care: One Center’s Experience

Expert Point of View: Nancy Baxter, MD, PhD & Steven H. Lin, MD, PhD

“CALGB 80803 really helps move the field forward,” said press briefing moderator and ASCO spokesperson Nancy Baxter, MD, PhD, a surgeon from St. Michael’s Hospital in Toronto, Ontario, Canada. “PET [positron-emission tomography] scans may prove to be a valuable tool to help oncologists fine-tune...


FDA Approves Maintenance Niraparib for Recurrent Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

The U.S. Food and Drug Administration (FDA) has approved niraparib (Zejula) for the maintenance treatment of adult patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer, whose tumors have achieved complete or partial response to platinum-based chemotherapy.


Solid Tumors

Shridar Ganesan, MD, PhD, on Mutation Burden and Immunotherapy

ASCO Launches Its New Journal Dedicated to Informatics

On February 23, 2017, ASCO launched its newest online-only journal, JCO Clinical Cancer Informatics (JCO CCI).

The first four articles published in JCO CCI are:

1) An editorial from JCO CCI Editor-in-Chief Debra A. Patt, MD, MPH, MBA, introducing the publication and laying out its objective of...

Guidelines Planned on Management of Immunotherapy Side Effects: ASCO and NCCN to Collaborate on Development

Given the pace of advances in immunotherapy in recent years and physicians’ need to keep up with these developments, ASCO and the National Comprehensive Cancer Network® (NCCN®) have announced a joint collaboration to publish practical clinical guidance on the management of side effects caused by...

ASCO and Cancer Care Ontario Update Guideline on Radiation Therapy for Prostate Cancer

The American Society of Clinical Oncology (ASCO) and Cancer Care Ontario today issued a joint clinical practice guideline update on brachytherapy for patients with prostate cancer. The update provides evidence-based recommendations for different patient risk groups and specifies the most effective...

Breast Cancer
Prostate Cancer
Issues in Oncology

Diana D. Jeffery, PhD, on Mental Health Comorbidities: Predictors of Cost and Utilization

Eric M. Horwitz, MD, Inducted Into Inaugural Class of Fellows of the American Brachytherapy Society

Eric M. Horwitz, MD, Chair of the Department of Radiation Oncology at Fox Chase Cancer Center, has been selected by the American Brachytherapy Society (ABS) as an inaugural ABS Fellow. Dr. Horwitz is among 12 fellows in the inaugural class. He will be formally recognized at the ABS 2017 Annual...


New Study Finds Most Cancer Mutations Due to Random DNA-Copying Errors

Johns Hopkins Kimmel Cancer Center scientists report data from a new study providing evidence that random, unpredictable DNA copying “mistakes” account for nearly two-thirds of the mutations that cause cancer. Their research is grounded on a novel mathematic model based on DNA...

click me